BioPharma Clinical Trials
Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort
Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...
September 17, 2025 | News
US, China and Australia Begin Phase 2 Trial of Atom Therapeutics’ ABP-745 for Acute Gout Flares
ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease Atom T...
September 17, 2025 | News
Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...
September 17, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...
September 16, 2025 | News
Biostar Pharma Doses First Patients in Two Global Phase II/III Trials of Oral Utidelone Capsule for Gastric and Ovarian Cancers
Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. ("Biostar", Stock Code: 2563.HK) which is a synthetic biolo...
September 16, 2025 | News
Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity
Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...
September 16, 2025 | News
LabConnect and OmniScience Partner to Launch Industry’s First AI Control Tower for Clinical Trial Lab Data
Together we're unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes. -- LabConn...
September 16, 2025 | News
BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...
September 16, 2025 | News
Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer
Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...
September 15, 2025 | News
Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma
Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...
September 15, 2025 | News
Pulnovo Medical Secures Dual FDA IDE Approvals and CMS Coverage for PADN Clinical Trials in the U.S.
Pulnovo Medical, a globally recognized leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), is proud to announce that its PADN...
September 15, 2025 | News
Mednovo Doses First Patient in Phase III Trial of Targeted Radiotherapeutic for GEP-NETs
Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodot...
September 12, 2025 | News
Kazia’s Paxalisib Disrupts Circulating Tumour Cell Clusters in HER2-Positive Metastatic Breast Cancer Study
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program...
September 12, 2025 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
